Equities Analysts Set Expectations for Eli Lilly and Co.’s FY2017 Earnings (LLY)
Eli Lilly and Co. (NYSE:LLY) – Stock analysts at Jefferies Group raised their FY2017 earnings per share (EPS) estimates for Eli Lilly and in a report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings of $4.26 per share for the year, up from their prior forecast of $4.12. Jefferies Group currently has a “Buy” rating and a $105.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.49 EPS and FY2020 earnings at $7.10 EPS.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the previous year, the firm posted $0.90 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year.
Several other research firms have also recently weighed in on LLY. Argus boosted their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. BMO Capital Markets reissued an “outperform” rating and set a $94.00 price objective on shares of Eli Lilly and in a research report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $89.00 to $95.00 in a research report on Tuesday, September 27th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $97.06.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/equities-analysts-set-expectations-for-eli-lilly-and-co-s-fy2017-earnings-lly.html
Eli Lilly and (NYSE:LLY) opened at 79.27 on Monday. The firm has a market cap of $83.84 billion, a price-to-earnings ratio of 34.17 and a beta of 0.17. Eli Lilly and has a 52-week low of $67.88 and a 52-week high of $88.16. The company’s 50-day moving average price is $79.73 and its 200-day moving average price is $77.79.
In other news, Director Jackson P. Tai acquired 2,560 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were purchased at an average cost of $80.42 per share, for a total transaction of $205,875.20. Following the transaction, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 1,213 shares of the stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Vanguard Group Inc. increased its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the period. Franklin Resources Inc. increased its position in Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares during the period. JPMorgan Chase & Co. increased its position in Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock worth $1,825,790,000 after buying an additional 668,184 shares during the period. Finally, BlackRock Fund Advisors increased its position in Eli Lilly and by 2.8% in the second quarter. BlackRock Fund Advisors now owns 17,206,391 shares of the company’s stock worth $1,355,003,000 after buying an additional 475,012 shares during the period. Hedge funds and other institutional investors own 74.99% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.